Pfizer begins phase III trial for vaccine against RSV
On the day after Bavarian Nordic received the promising results from the phase II trial for its vaccine against the RS virus, Pfizer announces its own vaccine candidate entering phase III.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
US pharmaceutical giant Pfizer enters phase III with its vaccine candidate against the RS virus, the company announces in a press release today.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
